Transmyocardial laser revascularization in ischemic cardiomyopathy

Area of Science:

• Cardiology
• Cardiovascular Surgery

Background:

• Ischemic cardiomyopathy (LVEF ≤ 30%) poses challenges for treatment, with coronary artery surgery often yielding better outcomes than heart transplantation.
• Transmyocardial laser revascularization (TMR) is a debated procedure potentially improving myocardial perfusion, possibly serving as a bridge or alternative to heart transplantation.

Purpose of the Study:

• To evaluate the efficacy of transmyocardial laser revascularization (TMR) in patients with ischemic cardiomyopathy (LVEF ≤ 30%).
• To assess TMR's impact on myocardial performance, survival rates, and its potential as an alternative to heart transplantation.

Main Methods:

• Retrospective analysis of 194 patients undergoing TMR (July 1997-October 1999).
• Exclusion of patients receiving TMR adjunctively with coronary artery surgery (n=30) and those without consent (n=8).
• Inclusion of 30 patients with ischemic cardiomyopathy (LVEF ≤ 30%) for analysis.

Main Results:

• Significant reduction in Canadian Cardiovascular Society (CCS) score and increase in maximum workload after 12 months.
• No significant improvement in thallium score or left ventricular ejection fraction (LVEF).
• 30-day, 1-year, and 2-year survival rates were 83%, 50%, and 47%, respectively.

Conclusions:

• TMR in ischemic cardiomyopathy presents a perioperative risk comparable to heart transplantation.
• The procedure does not enhance myocardial performance or prolong life expectancy, thus not serving as a bridge or alternative to transplantation.
• The anti-anginal effect of TMR may be justifiable in specific cases with contraindications for heart transplantation.